Patents by Inventor Ana Bernhard

Ana Bernhard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CNP PRODRUGS
    Publication number: 20230116746
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: June 23, 2022
    Publication date: April 13, 2023
    Inventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
  • CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY
    Publication number: 20220088206
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 24, 2022
    Inventors: Kennett SPROGØE, Harald RAU, Ana BERNHARD, Ulrich HERSEL, Felix CLEEMANN, Thomas WEGGE
  • Controlled-release CNP agonists with increased NEP stability
    Patent number: 11224661
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: January 18, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
  • CNP PRODRUGS
    Publication number: 20210069339
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: August 13, 2020
    Publication date: March 11, 2021
    Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
  • CNP PRODRUGS
    Publication number: 20190255183
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: February 6, 2019
    Publication date: August 22, 2019
    Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
  • CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY
    Publication number: 20190022237
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Inventors: Kennett SPROGØE, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
  • CNP PRODRUGS
    Publication number: 20170368189
    Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.
    Type: Application
    Filed: January 8, 2016
    Publication date: December 28, 2017
    Inventors: Kennett SPROGØE, Ulrich HERSEL, Harald RAU, Thomas WEGGE, Frank FALTINGER, Felix CLEEMANN, Nora KALUZA, Ana BERNHARD, Annette BUBA, Tom WOODS
  • Relaxin Prodrugs
    Publication number: 20160296600
    Abstract: The present invention relates to a carrier-linked relaxin prodrug, pharmaceutical compositions comprising said prodrug, their use as medicaments for the treatment of diseases which can be treated with relaxin, methods of application of such carrier-linked relaxin prodrug or pharmaceutical compositions, methods of treatment, and containers comprising such prodrug or compositions.
    Type: Application
    Filed: November 10, 2014
    Publication date: October 13, 2016
    Applicant: Ascendis Pharma Relaxin Division A/S
    Inventors: Kennett Sprogøe, Felix Cleemann, Harald Rau, Nicole Hassepass, Thomas Wegge, Joachim Zettler, Ana Bernhard